Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base
Included In Small-Cell Lung Cancer Guidelines In US For Second-Line Use
Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.
You may also be interested in...
The Madrid-based group's Aplidin is set to go back yet again to European regulators but the sea squirt-derived drug seems to be showing more potential in COVID-19 than in multiple myeloma.
The company plans to file for approval in the expanded indication, for which there are currently no approved therapies.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.